The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Single-center experience in French Temporary Authorization for Use (TAU) metastatic melanoma program with ipilimumab.
Francois Chasset
No relevant relationships to disclose
Cécile Pagès
No relevant relationships to disclose
Lucie Biard
No relevant relationships to disclose
Jennifer Roux
No relevant relationships to disclose
Irina Sidina
No relevant relationships to disclose
Isabelle Madelaine
No relevant relationships to disclose
Nicole Basset-Seguin
No relevant relationships to disclose
Manuelle Viguier
Consultant or Advisory Role - Bristol-Myers Squibb
Nika Madjlessi
No relevant relationships to disclose
Pierre Schneider
No relevant relationships to disclose
Martine Bagot
No relevant relationships to disclose
Matthieu Resche-Rigon
No relevant relationships to disclose
Celeste Lebbe
No relevant relationships to disclose